Gould Asset Management LLC CA grew its position in Pfizer Inc. (NYSE:PFE) by 6.0% in the third quarter, according to its most recent filing with the SEC. The fund owned 29,302 shares of the biopharmaceutical company’s stock after acquiring an additional 1,651 shares during the period. Gould Asset Management LLC CA’s holdings in Pfizer were worth $1,046,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Janus Henderson Group PLC raised its position in Pfizer by 243.5% during the 2nd quarter. Janus Henderson Group PLC now owns 13,175,187 shares of the biopharmaceutical company’s stock worth $442,574,000 after purchasing an additional 9,339,749 shares during the last quarter. Vanguard Group Inc. raised its position in Pfizer by 2.3% during the 2nd quarter. Vanguard Group Inc. now owns 418,639,111 shares of the biopharmaceutical company’s stock worth $14,062,088,000 after purchasing an additional 9,239,499 shares during the last quarter. Renaissance Technologies LLC bought a new position in Pfizer during the 2nd quarter worth $268,389,000. Canada Pension Plan Investment Board raised its position in Pfizer by 249.6% during the 2nd quarter. Canada Pension Plan Investment Board now owns 10,713,626 shares of the biopharmaceutical company’s stock worth $359,871,000 after purchasing an additional 7,649,416 shares during the last quarter. Finally, Longview Partners Guernsey LTD raised its position in Pfizer by 32.0% during the 3rd quarter. Longview Partners Guernsey LTD now owns 24,369,672 shares of the biopharmaceutical company’s stock worth $869,997,000 after purchasing an additional 5,901,100 shares during the last quarter. Institutional investors own 70.06% of the company’s stock.

Shares of Pfizer Inc. (NYSE PFE) opened at $34.94 on Wednesday. The company has a current ratio of 1.43, a quick ratio of 1.15 and a debt-to-equity ratio of 0.56. Pfizer Inc. has a 1-year low of $31.67 and a 1-year high of $39.43. The firm has a market capitalization of $208,270.00, a PE ratio of 9.93, a price-to-earnings-growth ratio of 1.93 and a beta of 0.94.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.62 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.56 by $0.06. The firm had revenue of $13.70 billion during the quarter, compared to the consensus estimate of $13.67 billion. Pfizer had a return on equity of 26.86% and a net margin of 40.55%. The business’s revenue was up .6% compared to the same quarter last year. During the same period last year, the business posted $0.47 EPS. sell-side analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 1st. Stockholders of record on Friday, February 2nd will be paid a $0.34 dividend. The ex-dividend date is Thursday, February 1st. This is an increase from Pfizer’s previous quarterly dividend of $0.32. This represents a $1.36 annualized dividend and a dividend yield of 3.89%. Pfizer’s dividend payout ratio (DPR) is currently 38.64%.

Pfizer announced that its Board of Directors has approved a stock buyback plan on Monday, December 18th that permits the company to repurchase $10.00 billion in shares. This repurchase authorization permits the biopharmaceutical company to repurchase shares of its stock through open market purchases. Stock repurchase plans are generally an indication that the company’s board of directors believes its stock is undervalued.

Several research analysts recently issued reports on the company. BMO Capital Markets set a $43.00 target price on Pfizer and gave the stock a “buy” rating in a research report on Monday, February 5th. Berenberg Bank set a $36.00 target price on Pfizer and gave the stock a “neutral” rating in a research report on Tuesday, January 30th. Societe Generale set a $40.00 target price on Pfizer and gave the stock a “neutral” rating in a research report on Wednesday, January 31st. Morningstar set a $38.00 target price on Pfizer and gave the stock a “neutral” rating in a research report on Tuesday, January 30th. Finally, UBS Group set a $42.00 target price on Pfizer and gave the stock a “buy” rating in a research report on Wednesday, January 31st. Two analysts have rated the stock with a sell rating, ten have issued a hold rating and eleven have assigned a buy rating to the company. Pfizer has a consensus rating of “Hold” and a consensus price target of $39.45.

In other news, insider Alexander R. Mackenzie sold 6,750 shares of the firm’s stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $37.00, for a total value of $249,750.00. Following the completion of the sale, the insider now directly owns 103,458 shares in the company, valued at approximately $3,827,946. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Rady A. Johnson sold 8,000 shares of the firm’s stock in a transaction dated Friday, December 15th. The shares were sold at an average price of $37.07, for a total value of $296,560.00. Following the completion of the sale, the executive vice president now owns 46,963 shares of the company’s stock, valued at $1,740,918.41. The disclosure for this sale can be found here. Company insiders own 0.06% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Gould Asset Management LLC CA Increases Stake in Pfizer Inc. (PFE)” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this report can be accessed at https://www.thecerbatgem.com/2018/02/14/gould-asset-management-llc-ca-increases-stake-in-pfizer-inc-pfe.html.

Pfizer Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.